Vnitr Lek 2012, 58(7-8):205-207

Chronic inflammation and the metabolic syndrome

Š. Svačina
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Metabolic syndrome is a disease associated with systemic inflammation. At present, metabolic syndrome is understood chiefly as an abdominal obesity with complications. Inflammatory signs then have the strongest association with the wasteline. Nevertheless, metabolic syndrome is most certainly also induced by an inflammation of a different origin. Metabolic syndrome is linked to typically inflammatory diseases such as paradontosis, rheumatoid diseases, chronic obstructive pulmonary disease and, to a large extent, psoriasis. The association is thus certainly reciprocal; metabolic syndrome causes inflammation and inflammatory diseases cause metabolic syndrome. Pathogenic relationships are unclear while it cannot be excluded that it is primarily an inflammation that causes metabolic syndrome and, in case of abdominal obesity without another inflammatory disease, this may be an inflammation in the abdominal fat.

Keywords: metabolic syndrome; type 2 diabetes mellitus; hypertension; paradontosis; C-reactive protein; chronic obstructive pulmonary disease; rheumatoid arthritis; psoriasis

Received: June 3, 2012; Published: July 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. Chronic inflammation and the metabolic syndrome. Vnitr Lek. 2012;58(7-8):205-207.
Download citation

References

  1. Wang M (ed.). Metabolic syndrome: Underlying Mechanisms and Drug Therapies. Hoboken, NJ, USA: John Wiley & Sons 2011. Go to original source...
  2. Svačina Š et al. Poruchy metabolismu a výživy. Praha: Galén 2010.
  3. Svačina Š et al. Metabolický syndrom. 3. rozř. a přeprac. vyd. Praha: Triton 2006.
  4. Svačina Š, Souček M, Šmahelová A et al. Metabolický syndrom. 1. vyd. Praha: Grada 2011.
  5. Strunecká A, Patočka J. Doba jedová 1. Praha: Triton 2011.
  6. Strunecká A, Patočka J. Doba jedová 2. Praha: Triton 2012.
  7. Oliveira AC, Oliveira AM, Adan LF et al. C-reactive protein and metabolic syndrome in youth: a strong relationship? Obesity (Silver Spring) 2008; 16: 1094-1098. Go to original source... Go to PubMed...
  8. Alonso-Rodríguez C, Medina-Font J. High sensitivity C-reactive protein in airline pilots with metabolic syndrome. Aviat Space Environ Med 2012; 83: 504-508. Go to original source... Go to PubMed...
  9. Zuliani G, Volpato S, Galvani M et al. Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study. Atherosclerosis 2009; 203: 626-632. Go to original source... Go to PubMed...
  10. Watz H, Waschki B, Kirsten A et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039-1046. Go to original source... Go to PubMed...
  11. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. Go to original source... Go to PubMed...
  12. Cohen AD, Sherf M, Vidavsky L et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155. Go to original source... Go to PubMed...
  13. Gelfand J, Azfar RS, Mehta NN. Psoriasis and Cardiovascular Risk: Strength in Numbers. J Invest Dermatol 2010; 130: 919-922. Go to original source... Go to PubMed...
  14. Brauchli YB, Jick SS, Curtin F et al. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol 2008; 58: 421-429. Go to original source... Go to PubMed...
  15. Mittal R, Malhotra S, Pandhi P et al. Efficacy and Safety of Combination Acitretin and Pioglitazone Therapy in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145: 387-393. Go to original source... Go to PubMed...
  16. Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab 2012; 38: 86-88. Go to original source... Go to PubMed...
  17. Farrokhi F, Taylor HC, McBride NM. Etanercept-induced hypoglycemia and improved glycemic control in a patient with type 2 diabetes. Endocr Pract 2011; 17: 306-307. Go to original source... Go to PubMed...
  18. Wambier CG, Foss-Freitas MC, Paschoal RS et al. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol 2009; 60: 883-885. Go to original source... Go to PubMed...
  19. Preshaw PM, Alba AL, Herrera D et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 2012; 55: 21-31. Go to original source... Go to PubMed...
  20. Han DH, Lim S, Paek D et al. Periodontitis could be related factors on metabolic syndrome among Koreans: a case-control study. J Clin Periodontol 2012; 39: 30-37. Go to original source... Go to PubMed...
  21. Vidal F, Figueredo CM, Cordovil I et al. Higher prevalence of periodontitis in patients with refractory arterial hypertension: a case-control study. Oral Dis 2011; 17: 560-563. Go to original source... Go to PubMed...
  22. Maňka V et al. Metabolický syndrom při zápalových onemocněních spojiva. Diabetes obezita 2003; 12: 85-92.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.